The extent of tumor cell lysis of CD19-DEK in the presence or absence eculizumab is significantly different at an antibody concentration of 2 μg/ml, whereas no significant difference in tumor cell lysis is observed at an antibody concentration of 0.016 μg/ml (Figure 4D). Here, CD19 is linked to neoplasm.